EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The importance of investing in data, models, experiments, team science, and public trust to help policymakers prepare for the next pandemic

Richard Grieve iD, Youqi Yang iD, Sam Abbott iD, Giridhara R Babu, Malay Bhattacharyya, Natalie Dean, Stephen Evans iD, Nicholas Jewell, Sinéad M Langan, Woojoo Lee iD, Geert Molenberghs, Liam Smeeth iD und 2 weitere

PLOS Global Public Health · 30.11.2023 · 3 (11) · e0002601

DOI: 10.1371/journal.pgph.0002601 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PLOS Global Public Health, online erschienen am 30.11.2023. Verfasst von Richard Grieve und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Data and Statistical Science for Health (DASH), London School of Hygiene and Tropical Medicine, London, United Kingdom. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIAID NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic has brought about valuable insights regarding models, data, and experiments. In this narrative review, we summarised the existing literature on these three themes, exploring the challenges of providing forecasts, the requirement for real-time linkage of health-related datasets, and the role of ‘experimentation’ in evaluating interventions. This literature review encourages us to broaden our perspective for the future, acknowledging the significance of investing in models, data, and experimentation, but also to invest in areas that are conceptually more abstract: the value of ‘team science’, the need for public trust in science, and in establishing processes for using science in policy. Policy-makers rely on model forecasts early in a pandemic when there is little data, and it is vital to communicate the assumptions, limitations, and uncertainties (theme 1). Linked routine data can provide critical information, for example, in establishing risk factors for adverse outcomes but are often not available quickly enough to make a real-time impact. The interoperability of data resources internationally is required to facilitate sharing across jurisdictions (theme 2). Randomised controlled trials (RCTs) provided timely evidence on the efficacy and safety of vaccinations and pharmaceuticals but were largely conducted in higher income countries, restricting generalisability to low- and middle-income countries (LMIC). Trials for non-pharmaceutical interventions (NPIs) were almost non-existent which was a missed opportunity (theme 3). Building on these themes from the narrative review, we underscore the importance of three other areas that need investment for effective evidence-driven policy-making. The COVID-19 response relied on strong multidisciplinary research infrastructures, but funders and academic institutions need to do more to incentivise team science (4). To enhance public trust in the use of scientific evidence for policy, researchers and policy-makers must work together to clearly communicate uncertainties in current evidence and any need to change policy as evidence evolves (5). Timely policy decisions require an established two-way process between scientists and policy makers to make the best use of evidence (6). For effective preparedness against future pandemics, it is essential to establish models, data, and experiments as fundamental pillars, complemented by efforts in planning and investment towards team science, public trust, and evidence-based policy-making across international communities. The paper concludes with a ‘call to actions’ for both policy-makers and researchers.

Autor:innen und Institutionen

  • Centre for Data and Statistical Science for Health (DASH), London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Indian Institute of Public Health, Public Health Foundation of India, Bengaluru, India.

ORCID-Profile: Richard Grieve, Youqi Yang, Sam Abbott, Stephen Evans, Woojoo Lee, Liam Smeeth

Förderung

  • Wellcome Trust
  • NIAID NIH HHS

Zitieren

APA

Grieve, R., Yang, Y., Abbott, S., Babu, G. R., Bhattacharyya, M., Dean, N., Evans, S., Jewell, N., Langan, S. M., Lee, W., Molenberghs, G., Smeeth, L., Williamson, E., & Mukherjee, B. (2023). The importance of investing in data, models, experiments, team science, and public trust to help policymakers prepare for the next pandemic. PLOS Global Public Health, 3(11), e0002601. https://doi.org/10.1371/journal.pgph.0002601

Vancouver

Grieve R, Yang Y, Abbott S, Babu GR, Bhattacharyya M, Dean N, et al. The importance of investing in data, models, experiments, team science, and public trust to help policymakers prepare for the next pandemic. PLOS Global Public Health. 2023;3(11):e0002601. doi:10.1371/journal.pgph.0002601

BibTeX
@article{Grieve2023,
  author = {Grieve, Richard and Yang, Youqi and Abbott, Sam and Babu, Giridhara R and Bhattacharyya, Malay and Dean, Natalie and Evans, Stephen and Jewell, Nicholas and Langan, Sinéad M and Lee, Woojoo and Molenberghs, Geert and Smeeth, Liam and Williamson, Elizabeth and Mukherjee, Bhramar},
  title = {The importance of investing in data, models, experiments, team science, and public trust to help policymakers prepare for the next pandemic},
  journal = {PLOS Global Public Health},
  year = {2023},
  volume = {3},
  number = {11},
  pages = {e0002601},
  doi = {10.1371/journal.pgph.0002601}
}
Kostenlos starten →